Latest Publications

Share:

FDA 2023-24: A Look Back & A Peek Forward

Most years are eventful for businesses regulated by the US Food and Drug Administration (“FDA”), and 2023 was no exception. 2024 promises more of the same – it being a Presidential election year, some FDA decisions (increased...more

HHS Finalized Part 2 Revisions: What Has Changed?

On February 8, 2024, the U.S. Department of Health and Human Services, through its Office for Civil Rights (OCR) and the Substance Abuse and Mental Health Services Administration (SAMHSA), released final rule (Final Rule)...more

DEA Issues Second Temporary Rule Extending Controlled Substance Prescribing Flexibilities Through December 2024

On October 6, 2023, the Drug Enforcement Agency (DEA) and the Department of Health and Human Services (HHS) issued a Second Temporary Rule, further extending the ability to prescribe controlled substances via telemedicine...more

FDA Modifies Mifepristone REMS Program, Establishes Certification Process for Pharmacies

On January 3, 2023, FDA released an updated Risk Evaluation and Mitigation Strategy (REMS) for mifepristone. The updated REMS follows a December 2021 FDA announcement that it would eliminate the requirement that mifepristone...more

Cybersecurity and “Recognized Security Practices”: New Statute modifies HIPAA

On January 5, 2020, President Trump signed into law H.R. 7898. This new statute amends the Health Information Technology for Economic and Clinical Health (HITECH) Act to require the Department of Health and Human Services...more

HIPAA Notice of Proposed Rulemaking

On December 10, 2020, the Department of Health and Human Services (HHS), Office for Civil Rights (OCR) issued a notice of proposed rulemaking (NPRM) to modify the Health Insurance Portability and Accountability Act (HIPAA)...more

What COVID-19 Means for FDA-Regulated Industry

U.S. and international health authorities continue to respond to the outbreak of the novel coronavirus (COVID-19). While originally detected in Wuhan City, Hubei Province, China, as of the date of this alert the virus has now...more

7 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide